Alamar Biosciences, Inc. ALMR

ALMR Company Overview

Alamar Biosciences, Inc. is a privately held life sciences and diagnostics technology company focused on precision proteomics and ultra-sensitive biomarker detection. The company operates within the biotechnology, life sciences tools, and clinical research industries, developing platforms designed to detect low-abundance proteins for applications in early disease detection, drug development, translational research, and precision medicine. Its primary commercial offerings include the NULISA™ Platform and the ARGO™ HT System, which are designed to improve sensitivity and multiplexing capabilities in proteomic analysis compared with conventional immunoassay technologies.

The company primarily serves pharmaceutical companies, academic research institutions, clinical laboratories, and biotechnology firms engaged in biomarker discovery and therapeutic development. Alamar Biosciences was founded in 2018 and has positioned itself within the growing proteomics market by emphasizing high sensitivity, broad dynamic range, and scalable assay workflows for neurological disease, oncology, immunology, and inflammation research. Publicly available information indicates that the company’s strategic differentiation centers on proprietary chemistry and assay architecture intended to enable earlier and more accurate detection of disease-associated proteins.